Accelerate Diagnostics, Inc. (AXDX)

Accelerate Diagnostics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-59.05	-61.62	-62.49	-77.7	-78.21	-84.31
Depreciation & Amortization	3.31	3.25	3	2.52	3	2.6
Share-Based Compensation	6.13	5.39	10.63	22.05	16.46	12.62
Other Operating Activities	14.33	12.78	0.14	5.81	8.35	4.29
Operating Cash Flow	-35.28	-40.2	-48.73	-47.32	-50.39	-64.79
Capital Expenditures	-1.54	-1.04	-0.55	-0.6	-1.36	-0.33
Change in Investments	1.47	9.7	12.97	8.91	14.97	53.14
Investing Cash Flow	-0.06	8.66	12.42	8.3	13.61	52.81
Share Issuance / Repurchase	14.23	4	33.1	44.83	6.42	6.82
Debt Issued / Paid	5.02	5.02	-1.47	-1.6	5.21	0
Other Financing Activities	1.29	-	-	-	-	-
Financing Cash Flow	20.54	9.02	31.63	43.23	11.63	6.82
Exchange Rate Effect	0.01	-0.25	-0.31	-0.09	-0.08	-0.09
Net Cash Flow	-14.8	-22.77	-4.99	4.12	-25.23	-5.25
Free Cash Flow	-36.82	-41.23	-49.28	-47.93	-51.76	-65.12
Free Cash Flow Margin	-302.57%	-341.91%	-386.46%	-406.77%	-463.56%	-700.48%
Free Cash Flow Per Share	-1.92	-3.31	-6.00	-7.76	-9.24	-11.95

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).